最終更新日：2022/12/24
Novel hydroxyamide compounds developed using rational drug designing approaches, based on the binding site of phenytoin to VGSCs, have demonstrated significant inhibition of voltage-gated sodium channel activities and increased inhibition of androgen–independent prostate cancer cell growth in vitro in comparison to phenytoin and significant ability to reduce prostate cancer in vivo as well [ 124, 158 ].
音声機能が動作しない場合はこちらをご確認ください
編集履歴（0）
元となった例文
Novel
hydroxyamide
compounds
developed
using
rational
drug
designing
approaches,
based
on
the
binding
site
of
phenytoin
to
VGSCs,
have
demonstrated
significant
inhibition
of
voltage-gated
sodium
channel
activities
and
increased
inhibition
of
androgen–independent
prostate
cancer
cell
growth
in
vitro
in
comparison
to
phenytoin
and
significant
ability
to
reduce
prostate
cancer
in
vivo
as
well
[
124,
158
].
